Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Review highlights next-generation cancer therapies targeting PIK3CA mutations February 25, 2025 Researchers identify neurons in a small brain region that delay feeding initiation July 11, 2024 Long-term effects of chemotherapy on hearing and quality of life in testicular cancer survivors June 28, 2024
Long-term effects of chemotherapy on hearing and quality of life in testicular cancer survivors June 28, 2024